Related Experiment Video
Updated: Aug 8, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC)
1Institute of Medical Biology, Chinese Academy of Medical Science, Jiaoling Road 379, Kunming, Yunnan 650118, P.R. China.
Introduction:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of malignant cells, but not in normal cells. This preferential toxicity to the abnormal cells renders TRAIL potentially a very powerful therapeutic weapon against cancer. However, a requirement for large quantities of TRAIL to suppress tumor growth in vivo is one of the major factors that has hindered it from being widely applied clinically. To overcome this, we constructed a replication-deficient adenovirus that carries a human full-length TRAIL gene (Ad-TRAIL) and tested its efficacy against a lung cancer model system in comparison to that of the recombinant soluble TRAIL protein.
Methods:
To investigate the antitumor activity and therapeutic value of the Ad-TRAIL on the non-small cell lung cancer (NSCLC), four NSCLC cell lines, namely, YTMLC, GLC, A549, and H460 cells, were used. TRAIL protein expression was determined by Western blotting and flow cytometry. Cell viability was analyzed by proliferation assay, and DNA ladder and cell-cycle analysis were used to identify apoptosis. To further evaluate the effect of Ad-TRAIL in vivo, YTMLC cells were inoculated to the subcutis of nude mice. The Ad-TRAIL was subsequently administered into the established tumors. Tumor growth and the TRAIL toxicity were evaluated after treatment.
Results:
YTMLC cells infected with Ad-TRAIL showed decreased cell viability and a higher percentage of apoptosis. Similar, Ad-TRAIL treatment also significantly suppressed tumor growth in vivo.
Conclusions:
TRAIL gene therapy provides a promising therapy for the treatment of NSCLC.
Insights
This study demonstrates that adenovirus-delivered Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) gene therapy effectively reduces non-small cell lung cancer cell viability and suppresses tumor growth in vivo.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, showing therapeutic potential.
- Clinical application of TRAIL is limited by the need for high doses to suppress tumor growth in vivo.
- Adenovirus-mediated gene delivery offers a strategy to enhance TRAIL's therapeutic efficacy.
Purpose of the Study:
- To evaluate the antitumor activity of a replication-deficient adenovirus carrying the human TRAIL gene (Ad-TRAIL) in non-small cell lung cancer (NSCLC).
- To compare the efficacy of Ad-TRAIL with recombinant soluble TRAIL protein in a preclinical lung cancer model.
Main Methods:
- Investigated Ad-TRAIL efficacy in four NSCLC cell lines (YTMLC, GLC, A549, H460).
- Assessed TRAIL protein expression, cell viability, and apoptosis induction (DNA ladder, cell-cycle analysis).
- Evaluated Ad-TRAIL's in vivo antitumor effect by administering it to established tumors in nude mice.
Main Results:
- Ad-TRAIL infection led to decreased cell viability and increased apoptosis in YTMLC cells.
- Significant suppression of tumor growth was observed in vivo following Ad-TRAIL treatment.
- Ad-TRAIL demonstrated potent antitumor activity in the preclinical NSCLC model.
Conclusions:
- TRAIL gene therapy using Ad-TRAIL is a promising therapeutic strategy for non-small cell lung cancer.
- Adenovirus-mediated delivery enhances TRAIL's efficacy, overcoming limitations of soluble protein administration.
- This approach holds potential for clinical application in NSCLC treatment.
More Related Videos
11:06Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
